Efficacy and Safety of BIO-K + CL1285 in Prevention of Antibiotic-associated Diarrhea in Hospitalized Adult Patients

A Double-blind, Randomized, Placebo Controlled, Multicenter Study of the Efficacy and Safety of BIO-K*+ CL-1285* in the Prevention of Antibiotic-associated Diarrhea in Adult Patients Exposed to Nosocomial Infection.

The purpose of this study is to evaluate the efficacy and safety of Bio-K + CL1285 versus placebo in the prevention of antibiotic-associated diarrhea in hospitalized adult patients.

Study Overview

• Status: Completed
• Conditions: Diarrhea; Clostridium Infections
• Intervention / Treatment: Dietary supplement: Lactobacillus acidophilus CL1285 and Lactobacillus casei; Dietary supplement: placebo

Detailed Description

Antibiotic-associated diarrhea (AAD) is one of the most frequent adverse events following antibiotherapy and is the leading cause of diarrhea in hospitalized patients. Ten to 25% of AAD are caused by the bacteria Clostridium difficile.

A recent unicenter study conducted at Maisonneuve-Rosemont hospital demonstrated the preventive role of Bio-K + CL1285 in antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea. Its preventive role is thought to be mainly through restoration of the gastrointestinal flora affected in part by the antibiotherapy.

A wide body of literature reveals clinical use of probiotics, but few well controlled prospective studies conducted on large numbers of subjects have been performed.

In light of the positive preliminary results obtained in a limited number of patients with AAD and of the paucity of well controlled clinical trials, we now wish to undertake a randomized, double blind, multicentre study to evaluate the efficacy and safety of Bio-K + CL1285 prophylaxis vs. placebo in the prevention of antibiotic-associated diarrhea in hospitalized adult patients. As secondary objectives, we also intend to evaluate the incidence of Clostridium difficile-associated diarrhea and to demonstrate that BIO-K + CL1285 agent will not only improve the clinical outcomes but also reduce health care expenditures.

• Study Type: Interventional
• Enrollment (Actual): 472
• Phase: Phase 3

Contacts and Locations

Study Locations

• Canada
  • Quebec, Canada, G1V 4G5
    • Laval Hospital
  • Ontario
    • Hamilton, Ontario, Canada, L8L-2X2
      • Hamilton General Hospital
    • Kingston, Ontario, Canada, K7L 2V7
      • Kingston General Hospital
    • Toronto, Ontario, Canada, M2K 1E1
      • North York General Hospital
  • Quebec
    • Chicoutimi, Quebec, Canada, G7H5H6
      • Hotel Dieu de Chicoutimi
    • Montreal, Quebec, Canada, H3T 1M5
      • St-Mary Hospital Center
    • St-Jerome, Quebec, Canada, J7Z 5T3
      • Hotel-Dieu de St-Jerome
    • Trois-Rivieres, Quebec, Canada, G8Z 3R9
      • Centre Hospitalier Regional de Trois-Rivieres

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• presenting to the Emergency Room and considered for admission to hospital for a minimum of 12 hours and requiring antibiotic administration for the treatment of a suspected or proven bacterial infection OR a hospitalized patient developing a suspected or proven nosocomial infection OR an external patient that come to the hospital for repeated visits to receive his intravenous antibiotic therapy for the treatment of a suspected or proven bacterial infection. The external patients on oral antibiotics that come to the hospital for repeated visits to receive any other treatments requiring a hospital stay of more than one hour will also be included.
• Hospital employee on antibiotics can also be included in the study
• having received less than 24 hours of antibiotic therapy;
• requiring a minimum of 3 days and a maximum of 14 days antibiotic administration

Informed consent must be obtained in writing for all subjects at enrollment into the study

Exclusion Criteria:

Subjects presenting with any of the following will not be included in the study:

• active diarrhea;
• a history of daily consumption of fermented milk and/or yogurt;
• intolerance to lactose;
• pregnant/breastfeeding women;
• an active, non controlled intestinal disease such as Crohn's Disease or ulcerative colitis;
• ileostomy, jejunostomy or colostomy;
• immunosuppressed state;
• a previous documented C. difficile infection in the three months prior to study initiation;
• active radiotherapy or chemotherapy;
• recent (< 6 months) or planned bone marrow graft or organ transplant;
• antibiotic therapy in the fourteen days prior to study initiation;
• the planned administration of metronidazole (alone or in combination) or vancomycin monotherapy for the treatment of an infection;
• mental or other conditions, or language barriers rendering the subject unable to understand the nature, scope, and possible consequences of the study or complete the self-administered questionnaires;
• subject unlikely to comply with protocol, e.g., uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study.

Post-enrollment exclusion criteria include fermented milk and/or yogurt consumption during the study period and two consecutive missed dose of study product.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: 1; Bio-K Cl1285 Bio-K Cl1285 contains 50 billion of live bacteria.	Dietary supplement: Lactobacillus acidophilus CL1285 and Lactobacillus casei; One bottle daily 2 hours before or after antibiotic administration and for 5 days following the termination of antibiotic regimen.; Other Names: BioK CL1285
Placebo Comparator: 2; placebo devoid of bacteria	Dietary supplement: placebo; One bottle daily 2 hours before or after antibiotic administration and for 5 days following the termination of antibiotic regimen.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The Incidence of Antibiotic-associated Diarrhea.	Presence of at least one diarrhea episode within 24 hours.	Up to 40 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Positive Results for Clostridium Difficile (C. Difficile) Toxin A or B in Antibiotic Associated Diarrhea Patients.	Testing for CDAD was performed at the discretion of the treating physician and according to the protocol in place at the study centers. CDAD was defined as an episode of diarrhea and positive results for C. difficile Toxin A or B.	Up to 40 days
Health Outcome Evaluation Will Look at the Direct Medical Costs and Clinical Outcomes of Alternative Strategies in the Prevention of Antibiotic-associated Diarrhea in Hospitalized Adult Patients		Up to 40 days
Safety Profile of BIO-K+CL1285® Versus Placebo in Patients on Antibiotics	Safety was assessed by the incidence of treatment-emerged adverse events, which were reported according to MedDRA 10.1	Up to 40 days

Collaborators and Investigators

• Sponsor: Bio-K Plus International Inc.
• Collaborators: JSS Medical Research Inc.
• Investigators: Principal Investigator: Joe S Dylewski, MD, St-Mary Hospital Center

Study record dates

Study Major Dates

• Study Start: March 1, 2006
• Primary Completion (Actual): March 1, 2007
• Study Completion (Actual): October 1, 2007

Study Registration Dates

• First Submitted: May 17, 2006
• First Submitted That Met QC Criteria: May 17, 2006
• First Posted (Estimate): May 19, 2006

Study Record Updates

• Last Update Posted (Estimate): August 7, 2014
• Last Update Submitted That Met QC Criteria: July 15, 2014
• Last Verified: July 1, 2014

More Information

Terms related to this study

• Keywords: Probiotics; Clostridium Difficile; Clostridium difficile-associated diarrhea; Lactobacillus acidophilus; Bio-K+CL1285; Antibiotics-associated diarrhea
• Additional Relevant MeSH Terms: Signs and Symptoms, Digestive; Bacterial Infections; Bacterial Infections and Mycoses; Gram-Positive Bacterial Infections; Infections; Diarrhea; Clostridium Infections
• Other Study ID Numbers: CL1285-AAD-M01